SLX “DP” IRMA kit

This product is an in vitro diagnostic reagent intended for the measurement of serum sialyl Le^x-i antigen (SLX)using the IRMA (Immunoradiometric Assay) method.

Serum SLX levels have been reported to be elevated in lung cancer, pancreatic cancer, and ovarian cancer, and are considered useful as an adjunctive aid in cancer diagnosis. In particular, a high positive rate has been observed in lung adenocarcinoma, with measured values increasing with disease stage and fluctuating with treatment efficacy. In addition, the positive rate in pancreatic cancer is also high, and further improvement in diagnostic performance may be expected when used in combination with other tumor markers. Furthermore, a low false-positive rate has been reported in non-malignant diseases.